Linda M. Meyer
Linda M. Meyer has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
Alfred Wegener
4 shared publicationsPer Söderberg
4 shared publicationsCarl-Ludwig Schönfeld
Herzog Carl-Theodor Eye Clinic Munich Germany
2 shared publicationsXiuqin Dong
St. Erik's Eye Hospital, Karolinska Institutet, Stockholm, Sweden
2 shared publicationsFrank Holz
1 shared publicationMarjorie Lou
1 shared publication
Latest Publications
- Open Access
- 1 August 2011
- Published by S. Karger AG in Case Reports in Ophthalmology
- Vol. 2 (2) , 246-250
Fast Resolution of Recurrent Pronounced Macular Edema following Intravitreal Injection of Dexamethasone 0.7 mg
Purpose: To report the fast resolution of recurrent pronounced macular edema due to central retinal vein occlusion (CRVO) within 72 h following intravitreal injection of dexamethasone 0.7 mg (Ozurdex®). Methods: An interventional case report with optical coherence tomography scans and fluorescein angiographic pictures. Results: A 69-year-old Caucasian man underwent intravitreal injection of dexamethasone 0.7 mg due to incomplete CRVO. He had previously undergone 6 intravitreal injections of bevacizumab 1.25 mg (Avastin®) and a C-grid laser photocoagulation over an interval of 16 months. After repeated recurrences of macular edema, the injection of dexamethasone reduced the macular edema from 570 µm preoperatively to 246 µm postoperatively within 72 h following the injection. Best-corrected visual acuity improved from 0.1 to 0.6 within the same interval. Conclusion: Dexamethasone can lead to a very fast reduction of macular edema in patients with vision loss due to CRVO and may facilitate an immediate visual rehabilitation. Retinal anatomy and visual acuity may be restored even in long-standing, recurrent cases.
- 1 August 2011
- Published by S. Karger AG in Case Reports in Ophthalmology
- Vol. 2 (2) , 246-250
Open AccessFast Resolution of Recurrent Pronounced Macular Edema following Intravitreal Injection of Dexamethasone 0.7 mg
Purpose: To report the fast resolution of recurrent pronounced macular edema due to central retinal vein occlusion (CRVO) within 72 h following intravitreal injection of dexamethasone 0.7 mg (Ozurdex®). Methods: An interventional case report with optical coherence tomography scans and fluorescein angiographic pictures. Results: A 69-year-old Caucasian man underwent intravitreal injection of dexamethasone 0.7 mg due to incomplete CRVO. He had previously undergone 6 intravitreal injections of bevacizumab 1.25 mg (Avastin®) and a C-grid laser photocoagulation over an interval of 16 months. After repeated recurrences of macular edema, the injection of dexamethasone reduced the macular edema from 570 µm preoperatively to 246 µm postoperatively within 72 h following the injection. Best-corrected visual acuity improved from 0.1 to 0.6 within the same interval. Conclusion: Dexamethasone can lead to a very fast reduction of macular edema in patients with vision loss due to CRVO and may facilitate an immediate visual rehabilitation. Retinal anatomy and visual acuity may be restored even in long-standing, recurrent cases.
- Open Access
- 1 January 2011
- Published by S. Karger AG in Case Reports in Ophthalmology
- Vol. 2 (3) , 319-322
Cystoid Macular Edema after Complicated Cataract Surgery Resolved by an Intravitreal Dexamethasone 0.7-mg Implant
Purpose: To report the effective treatment of cystoid macular edema (CME) following complicated cataract surgery (resulting in Irvine-Gass syndrome) with a dexamethasone 0.7-mg (Ozurdex®) intravitreal implant. Methods: An interventional case report with optical coherence tomography (OCT) scans. Results: An 83-year-old Caucasian woman was suffering from CME following complicated cataract surgery on her left eye. She had undergone 3 intravitreal injections of dexamethasone 0.4 mg in the 3 months following the surgery without any improvement of visual function. Seven months after the cataract surgery, she received a single intravitreal injection of dexamethasone 0.7 mg (Ozurdex). Four weeks following the injection, her best-corrected visual acuity improved from 0.3 to 0.8. CME resolved with a reduction of central retinal thickness from 393 µm pre-Ozurdex injection to 212 µm post-Ozurdex injection, as measured by OCT scan. Conclusion: Dexamethasone 0.7 mg (Ozurdex) has proven to be an effective treatment option in retinal vein occlusion and non-infectious uveitis. It can also be considered as off-label treatment in Irvine-Gass syndrome.
- 1 January 2011
- Published by S. Karger AG in Case Reports in Ophthalmology
- Vol. 2 (3) , 319-322
Open AccessCystoid Macular Edema after Complicated Cataract Surgery Resolved by an Intravitreal Dexamethasone 0.7-mg Implant
Purpose: To report the effective treatment of cystoid macular edema (CME) following complicated cataract surgery (resulting in Irvine-Gass syndrome) with a dexamethasone 0.7-mg (Ozurdex®) intravitreal implant. Methods: An interventional case report with optical coherence tomography (OCT) scans. Results: An 83-year-old Caucasian woman was suffering from CME following complicated cataract surgery on her left eye. She had undergone 3 intravitreal injections of dexamethasone 0.4 mg in the 3 months following the surgery without any improvement of visual function. Seven months after the cataract surgery, she received a single intravitreal injection of dexamethasone 0.7 mg (Ozurdex). Four weeks following the injection, her best-corrected visual acuity improved from 0.3 to 0.8. CME resolved with a reduction of central retinal thickness from 393 µm pre-Ozurdex injection to 212 µm post-Ozurdex injection, as measured by OCT scan. Conclusion: Dexamethasone 0.7 mg (Ozurdex) has proven to be an effective treatment option in retinal vein occlusion and non-infectious uveitis. It can also be considered as off-label treatment in Irvine-Gass syndrome.
- 1 December 2009
- Published by Elsevier in Experimental Eye Research
- Vol. 89 (6) , 833-839
Absence of glutaredoxin1 increases lens susceptibility to oxidative stress induced by UVR-B
- 1 December 2009
- Published by Elsevier in Experimental Eye Research
- Vol. 89 (6) , 833-839
Absence of glutaredoxin1 increases lens susceptibility to oxidative stress induced by UVR-B
- 1 February 2008
- Published by Elsevier in Experimental Eye Research
- Vol. 86 (2) , 282-289
Dose dependent cataractogenesis and Maximum Tolerable Dose (MTD2.3:16) for UVR 300nm-induced cataract in C57BL/6J mice
- 1 February 2008
- Published by Elsevier in Experimental Eye Research
- Vol. 86 (2) , 282-289
Dose dependent cataractogenesis and Maximum Tolerable Dose (MTD2.3:16) for UVR 300nm-induced cataract in C57BL/6J mice
- 10 October 2006
- Published by Wiley in Acta Ophthalmologica Scandinavica
- Vol. 85 (2) , 178-182
Light scattering in the C57BL/6 mouse lens
To characterize inherent light scattering in the C57BL/6 mouse lens. Lenses from 20 6-week-old female C57BL/6 mice were extracted from freshly enucleated globes and microsurgically cleaned of remnants of the ciliary body. Lens light scattering was measured quantitatively with a light dissemination meter (LDM). Morphological properties of the mouse lenses were documented using grid- and dark-field illumination photography. Analysis of variance was performed to establish variance for animals, variance between left and right eyes and variance for measurements. Average inherent light scattering in the C57BL/6 mouse lens is 0.16 +/- 0.02 tEDC (transformed equivalent diazepam concentration). The mean size of a mouse lens at 6 weeks is 1.9 mm in diameter. Two lenses featured pre-existing cortical lens opacities. Variance for animals was assessed to be 7.9 10(- 4) tEDC(2), variance for measurements was 1.6 10(- 4) tEDC(2), and variance between left and right eyes was 8.8 10(- 4) tEDC(2). The tolerance limit for non-pathological light scattering was determined to 0.26 tEDC. No significant difference in light scattering between left and right mouse lenses was found. The minimum number of C57BL/6 mice required for detection of a 10% experimentally induced change in light scattering intensity was estimated to be 50 for independent group experiments and 25 for paired design experiments. The C57BL/6 mouse is a suitable animal in which to conduct experiments on light scattering or cataractogenesis with high precision at reasonable sample sizes. Before including C57BL/6 mice into a study on cataractogenesis, pre-existing lens opacities such as congenital cataract must be excluded.
- 10 October 2006
- Published by Wiley in Acta Ophthalmologica Scandinavica
- Vol. 85 (2) , 178-182
Light scattering in the C57BL/6 mouse lens
To characterize inherent light scattering in the C57BL/6 mouse lens. Lenses from 20 6-week-old female C57BL/6 mice were extracted from freshly enucleated globes and microsurgically cleaned of remnants of the ciliary body. Lens light scattering was measured quantitatively with a light dissemination meter (LDM). Morphological properties of the mouse lenses were documented using grid- and dark-field illumination photography. Analysis of variance was performed to establish variance for animals, variance between left and right eyes and variance for measurements. Average inherent light scattering in the C57BL/6 mouse lens is 0.16 +/- 0.02 tEDC (transformed equivalent diazepam concentration). The mean size of a mouse lens at 6 weeks is 1.9 mm in diameter. Two lenses featured pre-existing cortical lens opacities. Variance for animals was assessed to be 7.9 10(- 4) tEDC(2), variance for measurements was 1.6 10(- 4) tEDC(2), and variance between left and right eyes was 8.8 10(- 4) tEDC(2). The tolerance limit for non-pathological light scattering was determined to 0.26 tEDC. No significant difference in light scattering between left and right mouse lenses was found. The minimum number of C57BL/6 mice required for detection of a 10% experimentally induced change in light scattering intensity was estimated to be 50 for independent group experiments and 25 for paired design experiments. The C57BL/6 mouse is a suitable animal in which to conduct experiments on light scattering or cataractogenesis with high precision at reasonable sample sizes. Before including C57BL/6 mice into a study on cataractogenesis, pre-existing lens opacities such as congenital cataract must be excluded.
- 1 October 2005
- Published by Elsevier in Experimental Eye Research
- Vol. 81 (4) , 389-394
UVR-B induced cataract development in C57 mice
- 1 October 2005
- Published by Elsevier in Experimental Eye Research
- Vol. 81 (4) , 389-394
UVR-B induced cataract development in C57 mice